ZNF22-AS1
Uncharacterized protein ZNF22-AS1
Also known as: ZFAS1_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for ZNF22-AS1 in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
122 residues, UniProt reviewed canonical sequence.
>Q5T742|ZNF22-AS1
1 MVPGPPESVV RFFLWFCFLL PPTRKASCDP RDLKSCNRPC VWSRLLKPNS SLSNLETAYF
61 PQILRFLRPW YFSRSHLNYH QKAPARWEWL YSIYRKGTKA QRRNVLRSPC APPQPSWPCS
121 VILocalizationUniProt · AlphaFold · HPA
Whether an antibody against ZNF22-AS1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.53
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Cellular components
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ZNF22-AS1 as an antibody target. Whether an autoantibody or antibody against ZNF22-AS1 could matter depends on whether native ZNF22-AS1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ZNF22-AS1 is annotated as secreted, so native ZNF22-AS1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label ZNF22-AS1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...